|
[1]
|
Hirvonen J, Aaho S, Lumme V, et al. Measurement of striatal and thalamic dopamine D2receptor binding with 11C-raclopfide[J]. Nucl Med Commun, 2003, 24(12):1207-1214. |
|
[2]
|
Brooks DJ, Ibanez V, Sawle GV, et al. Striatal D2receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopfide and positron emission tomography[J]. Ann Neurol, 1992, 31(2):184-192. |
|
[3]
|
Rinne JO, Laihinen A, Rinne UK, et al. D2 receptor changes during the progression of early Parkinson's disease[J]. Mov Disord, 1993, 8(2):134-138. |
|
[4]
|
Rinne JO, Laihinen A, Ruottinen H, et al. Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease:a PET study with[11C]raclopride[J]. J Neurol Sci, 1995, 132(2):156-161. |
|
[5]
|
Turjanski N, Lees AJ, Brooks DJ. In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias[J]. Neurology, 1997,49(3):717-723. |
|
[6]
|
Sawle GV, Playford ED, Brooks DJ, et al. Asymmetrical pre-synaptic and post-synpatic changes in the striatal dopamine projection in dopa naive parkinsonism:Diagnostic implications of the D2 receptor status[J]. Brain, 1993, 116(4):853-867. |
|
[7]
|
Antonini A, Schwarz J, Oertel WH, et al. long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease:a study with positron emission tomography and[11C]raclopride[J]. Mov Disord, 1997, 12(1):33-38. |
|
[8]
|
Goerendt IK, Messa C, Lawrence AD, et al. Dopamine release during sequential finger movements in health and Parkinson's disease:a PET study[J]. Brain, 2003, 126(2):312-325. |
|
[9]
|
Ouchi Y, Yoshikawa E, Futatsubashi M, et al. Effect of simple motor performance on regional dopamine release in the striatum in Parkinson disease patients and healthy subjects:a positron emission tomog-raphy study[J]. J Cereb Blood Flow Metab, 2002, 22(6):746-752. |
|
[10]
|
Tedroff J, Pedersen M, Aquilonius SM, et al. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by[11C] raclopride displacement and PET[J]. Neurology, 1996, 46(5):1430-1436. |
|
[11]
|
Fuente-Fernandez R, Lu JQ, Sossi V, et al. Biochemical variations in the synaptic level of dopamine precede motor flucmatinns in Parkinson's disease:PET evidence of increased dopamine turnover[J]. Ann Neurol, 2001, 49(3):298-303. |
|
[12]
|
Linazasoro G, Obeso JA, Gomez JC, et al. Modification of dopamine D2 receptor activity by pergolide in Parkinson's disease:an in vivo study by PET[J]. Clin Neuropharmacol, 1999, 22(5):277-280. |
|
[13]
|
Moresco RM, Volonte MA, Messa C, et al. New perspectives on neurochemical effects of amantadine in the brain of parkinsonian patients:a PET-[(11)C]raclopride study[J]. J Neural Transm, 2002,109(10):1265-1274. |
|
[14]
|
Piccini P, Pavese N, Brooks DJ. Endogenous dopamine release after pharmacological challenges in Parkinson's disease[J]. Ann Neurol,2003, 53(5):647-653. |
|
[15]
|
Hilker R, Voges J, Ghaemi M, et al. Deep brain stimulation of the subthalamic nucleus does not increase the striatal dopamine concentration in parkinsonian humans[J]. Mov Disord, 2003, 18(1):41-48. |
|
[16]
|
Piccini P, Brooks D J, Bjorklund A, et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient[J].Nat Neurosci, 1999, 2(12):1137-1140. |
点击查看大图
下载: